

Brilliant Violet 421™ anti-mouse IL-17A Antibody

Catalog# / Size	506925 / 125 µL 506926 / 50 µg
Clone	TC11-18H10.1
Regulatory Status	RUO
Other Names	Interleukin-17, Cytotoxic T lymphocyte-associated antigen 8 (CTLA-8)
Isotype	Rat IgG1, κ
Description	IL-17, also known as CTLA-8, is a T cell-expressed pleiotropic cytokine that exhibits a high degree of homology to a protein encoded by the ORF13 gene of herpes virus Saimiri. IL-17 is produced by Th cells (Th17) that are distinct from the traditional Th1- and Th2-cell subsets. IL-23 plays an important role in triggering IL-17 production. Both recombinant and natural IL-17 have been shown to exist as disulfide linked homodimers. IL-17 exhibits multiple biological activities on a variety of cells including: the induction of IL-6 and IL-8 production in fibroblasts, activation of NF-κB, and costimulation of T cell proliferation. IL-17 is an essential inflammatory mediator in the development of autoimmune diseases. Neutralization of IL-17 with monoclonal antibody is able to ameliorate the disease course.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	<i>E. coli</i> expressed, recombinant mouse IL-17A
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration	µg size: 0.2 mg/mL µL size: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	ICFC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis . For flow cytometric staining using the µL size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

[Learn more about Brilliant Violet™.](#)

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Excitation Laser	Violet Laser (405 nm)
-------------------------	-----------------------

Application Notes

ELISA Capture^{3,4} and ELISPOT Capture⁵. The purified TC11-18H10.1 antibody is useful as the capture antibody in a sandwich ELISA, when used in conjunction with the biotinylated TC11-8H4 antibody (Cat. No. 507002) as the detecting antibody and recombinant mouse IL-17 (Cat. No. 576009) as the standard.

Flow Cytometry^{2,4,7,8,11,12}. The TC11-18H10.1 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-17-producing cells within mixed cell populations.

Neutralization^{6,9}. The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for neutralization of mouse IL-17 bioactivity *in vivo* and *in vitro* (Cat. No. 506906).

Application References

(PubMed link indicates BioLegend citation)

1. Kennedy J, *et al.* 1996. *J. Interferon Cytokine Res.* 16:611.
2. Schubert D, *et al.* 2004. *J. Immunol.* 172:4503. (ICFC)
3. Infante-Duarte C, *et al.* 2000. *J. Immunol.* 165:6107. (ICFC, ELISA Capture)
4. Harrington LE, *et al.* 2005. *Nature Immunol.* doi:10.1038/ni1254. (ICFC, ELISA Capture)
5. Nekrasova T, *et al.* 2005. *J. Immunol.* 175:2734. (ELISPOT Capture)
6. Yen D, *et al.* 2006. *J. Clin. Invest.* 116:1310. (Neut)
7. Ehrchiou D, *et al.* 2007. *J. Exp. Med.* 204:1519. (ICFC)
8. Kang SG, *et al.* 2007. *J. Immunol.* 179:3724. (ICFC)
9. Smith E, *et al.* 2008. *J. Immunol.* 181:1357. (Neut) [PubMed](#)
10. Neufert C, *et al.* 2007. *Eur. J. Immunol.* 37:1809. [PubMed](#)
11. Wang C, *et al.* 2009. *Mucosal Immunol* 2:173. (ICFC) [PubMed](#)
12. Cui Y, *et al.* 2009. *Invest. Ophthalm. Vis. Sci.* 50:5811. (ICFC) [PubMed](#)
13. Kivisákk P, *et al.* 2009. *Ann. Neurol.* 65:457. [PubMed](#)
14. Cooney LA, *et al.* 2011. *J. Immunol.* 187:4440. [PubMed](#)
15. Ma Y, *et al.* 2012. *PLoS One.* 7:e40763. [PubMed](#)
16. Murakami R, *et al.* 2013. *PLoS One.* 8:73270. [PubMed](#)

Product Citations

1. Sanchez-Felipe L, *et al.* 2021. *Nature.* 590:320. [PubMed](#)
2. Sharma NS, *et al.* 2020. *J Clin Invest.* 130:451. [PubMed](#)
3. Haertel E, *et al.* 2018. *Eur J Immunol.* 48:1001. [PubMed](#)
4. Nagai Y, *et al.* 2019. *Front Immunol.* 10:174. [PubMed](#)
5. Findlay EG, *et al.* 2019. *Oncoimmunology.* 8:1608106. [PubMed](#)
6. Ning X, *et al.* 2019. *Mol Cell.* 74:19. [PubMed](#)
7. Palathingal Bava E, *et al.* 2022. *JCI Insight.* 7:. [PubMed](#)
8. Alves C, *et al.* 2015. *PLoS One.* 10: 0142972. [PubMed](#)
9. Yang L, *et al.* 2021. *Cell Death Differ.* 28:2616. [PubMed](#)
10. Jing Y, *et al.* 2020. *Sci Adv.* 6:eaax9455. [PubMed](#)
11. Shen X, *et al.* 2021. *Front Immunol.* 12:710750. [PubMed](#)
12. Sendler M, *et al.* 2020. *Gastroenterology.* 158:253. [PubMed](#)
13. Bergink V, *et al.* 2013. *Biol Psychiatry.* 73:1000. [PubMed](#)
14. Cabrera-Perez C, *et al.* 2015. *J Immunol.* 194:1609-20. [PubMed](#)
15. Leeansyah E, *et al.* 2013. *Blood.* 121:1124. [PubMed](#)
16. Kim M, *et al.* 2018. *Immunity.* 49:151. [PubMed](#)
17. Gupta S, *et al.* 2022. *Life Sci.* 288:120182. [PubMed](#)
18. Kawabe T, *et al.* 2013. *J Immunol.* 190:5788. [PubMed](#)
19. Chong WP, *et al.* 2020. *Immunity.* 53(2):384-397.e5.. [PubMed](#)
20. Hirota K *et al.* 2018. *Immunity.* 48(6):1220-1232. [PubMed](#)
21. Du Z, *et al.* 2020. *J Allergy Clin Immunol.* [PubMed](#)
22. Zeng F, *et al.* 2021. *J Invest Dermatol.* 596:141. [PubMed](#)

RRID

AB_10900442 (BioLegend Cat. No. 506925)
AB_2632611 (BioLegend Cat. No. 506926)

Antigen Details

Structure	Cytokine; dimer; 15 kD (Mammalian).
Bioactivity	Secretion of IL-6, IL-8, G-CSF, prostaglandin E2 by epithelial, endothelial or fibroblastic cells; stimulates cell migration, cord formation, and IL-6 secretion by stromal cells
Cell Sources	CD4 ⁺ memory T cells
Cell Targets	Fibroblasts, epithelial and endothelial cells, stromal cells
Receptors	IL-17R (CD217)
Biology Area	Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family	Cytokines/Chemokines
Antigen References	<ol style="list-style-type: none">1. Fitzgerald K, <i>et al.</i> Eds. 2001. <i>The Cytokine FactsBook.</i> Academic Press San Diego.2. Numasaki M, <i>et al.</i> 2002. <i>Blood</i> 101:2620.3. Fossiez F, <i>et al.</i> 1996. <i>J. Exp. Med.</i> 183:2593.

4. Yao Z, et al. 1997. *Cytokine* 9:794.
5. Dong C. 2006. *Nat. Rev. Immunol.* 6:329.
6. Hofstetter HH, et al. 2005 *Cell. Immunol.* 237:123.

Gene ID [16171](#)

Related Protocols


[Surface and Intracellular Cytokine Staining for Flow Cytometry - Video](#)

[Intracellular Flow Cytometry Staining Protocol](#)

Other Formats

PE anti-mouse IL-17A, Purified anti-mouse IL-17A, FITC anti-mouse IL-17A, Alexa Fluor® 488 anti-mouse IL-17A, Alexa Fluor® 647 anti-mouse IL-17A, Alexa Fluor® 700 anti-mouse IL-17A, APC anti-mouse IL-17A, Pacific Blue™ anti-mouse IL-17A, PerCP/Cyanine5.5 anti-mouse IL-17A, PE/Cyanine7 anti-mouse IL-17A, Brilliant Violet 421™ anti-mouse IL-17A, Brilliant Violet 605™ anti-mouse IL-17A, Brilliant Violet 650™ anti-mouse IL-17A, Brilliant Violet 785™ anti-mouse IL-17A, Brilliant Violet 510™ anti-mouse IL-17A, Purified anti-mouse IL-17A (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse IL-17A, APC/Cyanine7 anti-mouse IL-17A, Brilliant Violet 711™ anti-mouse IL-17A, PerCP anti-mouse IL-17A, Ultra-LEAF™ Purified anti-mouse IL-17A

Product Data



Th17-polarized C57BL/6 mouse CD4+ lymphocytes were stimulated with PMA + ionomycin for 6 hours in the presence of monensin, stained with CD4 FITC, fixed, permeabilized, and then stained with IL-17A (clone TC11-18H10.1) Brilliant Violet 421™ (top) or rat IgG1, κ Brilliant Violet 421™ isotype control (bottom).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587